LLLongting Lin

Longting Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Longting Lin has a total of 285 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CRCS‐K Imaging Repository: Architecture, Data Characteristics, and a Proof‐of‐Concept Analysis of Pretreatment Imaging Workflow

    by Beom Joon Kim, Wi‐Sun Ryu, Myung Jae Lee, Kyusik Kang, Jae Guk Kim, Soo Joo Lee, Jae‐Kwan Cha, Tai Hwan Park, Jeong‐Yoon Lee, Kyungbok Lee, et al.

    Background: Stroke registries have advanced cerebrovascular research but usually reduce neuroimaging to categorical variables, losing multidimensional information. We describe the CRCS‐K (Clinical Research Collaboration for Stroke in Korea) Imaging Repository, a multicenter platform integrating stroke imaging, artificial intelligence‐based quantification, and clinical and outcome data through a dedicated research platform, Artificial Intelligence Powered Stroke Clinical‐Image Archive Network (AISCAN). Methods: Building upon the nationwide CRCS‐K registry, the Imaging Repository collected all computed tomography, magnetic resonance, and angiographic studies obtained during index hospitalization from consecutive patients with acute ischemic stroke at 18 stroke centers. Images underwent centralized deidentification, quality verification, sequence classification, and artificial intelligence‐based quantification. As a proof‐of‐concept application, we examined associations of pretreatment imaging modality with treatment workflow and functional outcomes after intravenous thrombolysis or endovascular treatment. Results: From June 2022 through May 2025, 225 159 imaging sequences were collected from 20 792 patients. AI modules generated standardized numeric features including ischemic lesion volumes, perfusion parameters, white matter hyperintensity burden, and cerebral microbleed counts. Magnetic resonance‐first workflows varied substantially across centers, from 1.0% to 56.7%. Greater pretreatment imaging sequence burden was associated with longer door‐to‐treatment times after intravenous thrombolysis and endovascular treatment. In overlap‐weighted analyses, magnetic resonance‐based versus computed tomography‐based imaging was associated with directionally lower, but not statistically significant, odds of a favorable 3‐month outcome after intravenous thrombolysis (odds ratio [OR], 0.90 [95% CI, 0.70–1.18]) and endovascular treatment (OR, 0.89 [95% CI, 0.65–1.21]). Conclusions: Prospective, sequence‐level retention of all stroke neuroimaging is feasible at network scale and can be integrated with artificial intelligence‐derived features and clinical outcomes. This resource enables real‐world investigation of imaging workflows and outcomes.

  • No Reflow at Perfusion Imaging: Thresholds That Distinguish Functional and Tissue Outcome Groups in Acute Stroke

    by Tianqi Xu, Chushuang Chen, Nathan W. Manning, Andrew K. Cheung, Dennis J. Cordato, Christopher Blair, Beom Joon Kim, Jianhong Yang, Gang Li, Mark Parsons, et al.

    In patients with successful angiographic recanalization after endovascular thrombectomy (EVT), the presence of a lesion with delay time longer than 4 seconds appeared to be the most informative no-reflow definition at 24-hour post-EVT CT or MR perfusion imaging.


  • Open Access

    Serial Computed Tomography Perfusion and Diffusion Imaging After Complete Recanalization in Large‐Vessel Occlusion

    by Nakhoon Kim, Wi‐Sun Ryu, Leonard Sunwoo, Younbeom Jeong, Jun Yup Kim, Jihoon Kang, JoonNyung Heo, Sung Hyun Baik, Cheolkyu Jung, Moon‐Ku Han, et al.

    Background: Infarct evolution on diffusion‐weighted imaging (DWI) after complete recanalization and its relationships to computed tomography perfusion core and outcome remain uncertain. Methods: From a multicenter registry (2014–2024), we identified 189 patients with anterior‐circulation large‐vessel occlusion, modified Thrombolysis in Cerebral Infarction grade 3 recanalization, prethrombectomy computed tomography perfusion, immediate DWI within 24 hours, and delayed DWI at 24 to 168 hours. Robust linear regression identified predictors of DWI volume change; logistic regression assessed 90‐day modified Rankin Scale scores of 0 to 2. Results: DWI volume increased in 162 of 189 patients (85.7%), from a median of 4.8 mL (interquartile range, 1.1–16.4) immediately after thrombectomy to 11.7 mL (interquartile range, 3.8–40.2) on delayed imaging; the median change was 4.4 mL (interquartile range, 0.7–14.8). Baseline computed tomography perfusion core was method‐sensitively associated with greater change in the full model without immediate DWI (β=0.154 [heteroscedasticity‐consistent 95% CI, −0.024 to 0.332]; P =0.09; bootstrap 95% CI, 0.018–0.336; P =0.014) and attenuated after immediate DWI adjustment (β=0.100; P =0.22; bootstrap P =0.077). Each decile increase in volume change was associated with lower odds of functional independence (adjusted odds ratio, 0.81 [95% CI, 0.68–0.97]; P =0.021). Delayed DWI showed the best outcome discrimination. Conclusions: DWI‐defined infarct volume increased after complete recanalization and was associated with functional outcome. The core association was method‐sensitive and attenuated after accounting for immediate DWI, supporting a possible mediated rather than independent pathway.

  • Tenecteplase Efficacy in Patients With Distal Occlusions: Secondary Analysis of the TASTE Randomized Clinical Trial

    by Vignan Yogendrakumar, Justin Phung, Hannah T. Johns, Leonid Churilov, Carlos Garcia-Esperon, Gagan Sharma, Niruta Dhimal, Chushuang Chen, Longting Lin, Beng Lim Chew, et al.

    BACKGROUND: Tenecteplase has been previously evaluated in large- and medium-sized vessel occlusion subgroups, but its effectiveness in more distal occlusions, particularly those involving the distal middle cerebral artery branches or the anterior cerebral artery and posterior cerebral artery territories, and across varying ischemic core and perfusion profiles, remains uncertain. METHODS: We performed a secondary analysis of TASTE (Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation), a randomized clinical trial comparing tenecteplase and alteplase in patients presenting within 4.5 hours of symptom onset with perfusion imaging-confirmed stroke and evidence of target mismatch (penumbra/core ratio >1.8 and an absolute difference >15 mL). The primary outcome was the modified Rankin Scale (mRS) score of 0 to 1 at 90 days. We compared the effect of tenecteplase versus alteplase in subgroups based on occlusion site (proximal M2, distal M2, M3 and beyond, anterior cerebral artery, and posterior cerebral artery), ischemic core, core growth rate, and penumbra. The treatment effect of tenecteplase and alteplase was compared stratifying by the subgroup of interest, adjusting for age, baseline National Institutes of Health Stroke Scale score, and premorbid mRS score in modified Poisson regression models. RESULTS: Of the 680 patients enrolled, 492 were included in the primary analysis (median age, 73 [interquartile range, 63–82] years; male sex: 306/492 [62%]). Two hundred forty-two (49%) received tenecteplase, and 250 (51%) received alteplase. Tenecteplase was associated with a higher proportion of mRS score of 0 to 1 with distal (M3 and beyond) occlusions (tenecteplase: 62/81 [77%] versus alteplase: 59/93 [63%]; adjusted risk ratio, 1.23 [95% CI, 1.04–1.46]). Numerically higher rates of mRS score of 0 to 1 were observed with distal M2 (tenecteplase: 30/46 [65%] versus alteplase 28/48 [58%]; adjusted risk ratio, 1.14 [95% CI, 0.84–1.54]) and anterior cerebral artery occlusions (tenecteplase: 12/21 [57%] versus alteplase 5/13 [38%]; adjusted risk ratio, 1.46 [95% CI, 0.71–3.00]). No treatment differences were seen for proximal M2 or posterior cerebral artery occlusions ( P interaction across all occlusion sites: 0.89). Across ischemic core, penumbra, and core growth rate subgroups, no difference in treatment effect was observed. CONCLUSIONS: Patients with distal middle cerebral artery occlusions who are treated with tenecteplase are more likely to achieve an mRS score of 0 to 1 at 90 days than those treated with alteplase. REGISTRATION: URL: https://www.anzctr.org.au ; Unique identifier: ACTRN12613000243718.

  • Safety of Rapid Local Ischemic Postconditioning After Thrombectomy in Acute Stroke: A Dose-Finding Trial (RAPID SAVE)

    by Jiangshan Deng, Tingyu Yi, Yining Tao, Guangchen He, Liming Wei, Haitao Lu, Qing Zhou, Feng Shi, Congguo Yin, Gang Li, et al.

    BACKGROUND: Rapid local ischemic postconditioning may protect the brain after acute ischemic stroke, but its safety and optimal dosing in successfully reperfused patients after mechanical thrombectomy remain undefined. METHODS: This investigator-initiated, prospective, adaptive, multicenter phase I single-arm dose-finding trial employed a Bayesian Optimal Interval (Bayesian Optimal Interval Phase I/II) design. Patients with anterior circulation large-vessel occlusion and modified Thrombolysis in Cerebral Infarction 2b/3 reperfusion were enrolled without randomization. Within 5 minutes of recanalization, rapid local ischemic postconditioning was delivered via a balloon-guiding catheter positioned at the ipsilateral C1–intracranial internal carotid artery, alternating inflation/deflation to interrupt antegrade flow. Six dose levels were prespecified by inflation/deflation durations and cycles: 15/15s ×5; 1/1, 2/2, 3/3, 4/4, and 5/5 minutes ×4. The dose-limiting toxicity (including malignant infarction, procedure-related complications requiring treatment, or other procedure-attributable serious adverse events) threshold was 15%. The efficacy target (absence of infarct growth >10 mL at 72 hours) was 60%. Doses were eliminated if the posterior probability that toxicity exceeded 15% was ≥0.95 or efficacy <60% was ≥0.90. The dose with the highest utility meeting these criteria was selected. RESULTS: Five cohorts (n=25, 5 each) were enrolled. Four cohorts received 2/2 minutes×4 (n=20): 14 met the efficacy end point (posterior probability true efficacy 15%, ≈0.16). One cohort received 3/3 minutes×4 (n=5): 3 met the efficacy end point (probability true efficacy 15%, ≈0.95). This triggered the predefined safety rule, preventing further testing at 3/3-minute and higher doses. Bayesian Optimal Interval Phase I/II selected 2/2 minutes×4 as the optimal regimen with a favorable efficacy-toxicity profile. CONCLUSIONS: Rapid local ischemic postconditioning initiated immediately after thrombectomy was feasible. The 2/2 minutes×4 regimen met prespecified safety and efficacy thresholds and warrants evaluation in a larger, definitive trial. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06526429.


  • Clinical characteristics and outcomes of tandem lesions involving internal carotid artery occlusion and distal middle cerebral artery occlusion

    by Shinya Tomari, Thomas Lillicrap, Carlos Garcia-Esperon, Yumi Tomari Kashida, Yuji Shiga, Melody Zhang, Andrew Bivard, Longting Lin, Ferdinand Miteff, Mark W. Parsons, et al.

  • Clinical Impact of Postrecanalization Hemorrhagic Transformation and Its Prediction Using Baseline Noncontrast CT

    by Hee-Jung Ha, Wi-Sun Ryu, Leonard Sunwoo, Myungjae Lee, Kyusik Kang, Jae Guk Kim, Soo Joo Lee, Jae-Kwan Cha, Tai Hwan Park, Jeong-Yoon Lee, et al.

    BACKGROUND: Hemorrhagic transformation (HT) after recanalization therapy remains a critical concern in acute ischemic stroke management. While severe hemorrhages clearly worsen outcomes, the prognostic impact of mild HT and its optimal prediction methods remain uncertain. In this study, we aimed to evaluate the clinical significance of all HT subtypes and develop automated HT prediction models based on noncontrast computed tomography (CT) images. METHODS: We analyzed 2211 patients receiving intravenous thrombolysis, endovascular thrombectomy, or both from the multicenter Clinical Research Collaboration for Stroke in Korea Imaging repository (2022–2024). HT was classified on follow-up imaging of magnetic resonance or CT. Baseline ischemic lesion volume and Alberta Stroke Program Early CT Score–based net water uptake were quantified on baseline noncontrast CT. Multivariable regression was used to assess the association of HT and 90-day modified Rankin Scale scores. The performance of HT prediction models was compared, the automated imaging model versus established scores (hemorrhage after thrombolysis score and SEDAN), using the area under the curve. RESULTS: HT occurred in 41.2% of patients (hemorrhagic infarction [HI] 1: 13.8% and HI2: 16.8%, parenchymal hematoma [PH] 1: 6.5% and PH2: 4.1%). All HT subtypes independently predicted worse functional outcomes with stepwise increasing odds ratios: HI1 (1.77 [95% CI, 1.40–2.22]), HI2 (2.83 [95% CI, 2.27–3.53]), PH1 (4.65 [95% CI, 3.41–6.36]), and PH2 (14.76 [95% CI, 9.61–22.90]). This association persisted across treatment modalities and vascular territories. For PH prediction, the automated imaging model (noncontrast CT imaging markers combined with clinical variables) achieved superior performance (area under the curve, 0.77 [95% CI, 0.73–0.80]) compared with hemorrhage after thrombolysis score (0.71 [95% CI, 0.68–0.75]) and SEDAN (0.72 [95% CI, 0.69–0.76]) scores (both P <0.01 for area under the curve comparison). CONCLUSIONS: Even mild HI was independently associated with poor functional outcomes after reperfusion therapy. Automated noncontrast CT–derived biomarkers provide superior HT risk prediction compared with conventional scores, offering a practical tool for individualized stroke management in the reperfusion era.


  • Open Access

    Clinical Research Collaboration for Stroke in Korea Imaging Repository: A Prospective Multicenter Neuroimaging Repository

    by Beom Joon Kim, Wi-Sun Ryu, Myung Jae Lee, Kyusik Kang, Jae Guk Kim, Soo Joo Lee, Jae-Kwan Cha, Tai Hwan Park, Jeong-Yoon Lee, Kyungbok Lee, et al.

    Background: Prospective stroke registries have advanced our understanding of cerebrovascular disease, yet most reduce neuroimaging to categorical variables, forfeiting the multidimensional information inherent in clinical imaging. We describe the CRCS-K Imaging Repository, a prospective multicenter platform that systematically collects all stroke neuroimaging and integrates artificial intelligence (AI)-based automated quantification with clinical and outcome data through a dedicated research platform, AISCAN. Methods: Building upon the Clinical Research Collaboration for Stroke in Korea (CRCS-K), a nationwide prospective registry, all neuroimaging (computed tomography [CT], magnetic resonance [MR], and angiography) performed during index hospitalization of consecutive acute ischemic stroke patients was collected from 18 comprehensive stroke centers. Imaging underwent centralized quality verification, sequence classification, and AI-based quantification. As a proof-of-concept application, we examined the association between pre-treatment imaging modality, treatment workflow efficiency, and functional outcomes in patients receiving intravenous thrombolysis (IVT) or endovascular treatment (EVT). Results: From June 2022 through May 2025, 225,159 imaging sequences were collected from 20,792 patients. AI-based quantification modules converted these into standardized numeric features encompassing ischemic lesion volumes, perfusion parameters, white matter hyperintensity burden, and cerebral microbleed counts. Substantial inter-hospital variation in imaging modality selection was observed, with MR-first workflows ranging from 1.0% to 56.7% across centers. In the proof-of-concept analysis, each additional imaging sequence was associated with prolonged door-to-treatment times for both IVT and EVT. Propensity score overlap-weighted analyses suggested numerically more favorable functional outcomes with CT-based imaging among EVT-treated patients, whereas differences among IVT-treated patients were smaller and less consistent. Conclusions: The CRCS-K Imaging Repository demonstrates the feasibility of large-scale, prospective neuroimaging collection integrated with AI-based quantification and clinical data. The infrastructure enables clinically consequential questions that conventional registries cannot address.


  • Open Access

    Machine learning for triage of strokes with large vessel occlusion using photoplethysmography biomarkers

    by Márton Á Goda, Helen Badge, Jasmeen Khan, Yosef Solewicz, Moran Davoodi, Rumbidzai Teramayi, Dennis Cordato, Longting Lin, Lauren Christie, Christopher Blair, et al.

    Objective. Large vessel occlusion (LVO) stroke presents a major challenge in clinical practice due to the potential for poor outcomes with delayed treatment. Treatment for LVO involves highly specialized care, in particular endovascular thrombectomy, and is available only at certain hospitals. Therefore, prehospital identification of LVO by emergency ambulance services, can be critical for triaging LVO stroke patients directly to a hospital with access to endovascular therapy. Clinical scores exist to help distinguish LVO from less severe strokes, but they are based on a series of examinations that can be time-consuming and may be impractical for patients with dementia or those who cannot follow commands due to their stroke. There is a need for a fast and reliable method to aid in the early identification of LVO. In this study, our objective was to assess the feasibility of using 30 s photoplethysmography (PPG) recording to assist in recognizing LVO stroke. Approach. A total of 88 patients, including 25 with LVO, 27 with stroke mimic (SM), and 36 non-LVO stroke patients (NL), were recorded at the Liverpool Hospital emergency department in Sydney, Australia. Demographics (age, sex), as well as morphological features and beating rate variability measures, were extracted from the PPG. A binary classification approach was employed to differentiate between LVO stroke and NL + SM (NL.SM). A 2:1 train-test split was stratified and repeated randomly across 100 iterations. Main results. The best model achieved a median test set area under the receiver operating characteristic curve of 0.77 (0.71–0.82). Significance. Our study demonstrates the potential of utilizing a 30 s PPG recording for identifying LVO stroke.


  • Cost-Effectiveness of Endovascular Thrombectomy in Large Vessel Occlusion Stroke for the Very Elderly

    by Peter Lee, Teddy Wu, Chushuang Chen, Longting Lin, Carlos Garcia-Esperon, Dennis John Cordato, Ferdinand Miteff, Timothy John Kleinig, Philip Man Chiu Choi, Cheng Xin, et al.

    Endovascular thrombectomy (EVT) is associated with considerable clinical benefits for patients after large vessel occlusion (LVO) stroke. However, EVT remains underused in Australia, particularly among the very elderly (aged ≥80 years). The aim of this study was to evaluate the cost-effectiveness and clinical effectiveness of EVT vs standard medical management among very elderly patients using real-world, observational data. A modeled cost-effectiveness study was conducted from the Australian health care perspective. Data from a retrospective cohort of patients aged 80 years or older treated with EVT at 4 comprehensive stroke centers across Australia and New Zealand, as well as data from the International Stroke Perfusion Imaging Registry, were used to inform our economic analyses. The distribution of 90-day modified Rankin Scale (mRS) outcomes after propensity score matching was used to inform a decision-analytic Markov model. Costs and utility data for calculating quality-adjusted life years (QALYs) were drawn from published sources. The primary outcome of this analysis was the incremental cost-effectiveness ratio (ICER) in terms of cost per QALY gained for EVT compared with medical management. Uncertainty was evaluated with deterministic and probabilistic sensitivity analyses. A total of 548 patients (mean age 85.1 years and 296 women [54%]) were included to inform the propensity score matching analysis. After propensity score matching, the proportion of patients with favorable (mRS score ≤2) outcomes was higher for EVT vs standard care (37% vs 18%). Based on the modeled cost-effectiveness analysis comprising a hypothetical sample of 10,000 patients, EVT was estimated to prevent 471 deaths over a period of 15 years. On a per-patient basis, EVT was associated with a gain of 0.95 years of life and 0.97 QALYs at a net cost of AU$3,399. That is, from a health care perspective, EVT is cost-effective for very elderly patients with LVO stroke (ICER: $3,508 per QALY). Sensitivity analyses supported the robustness of the model, with 100% of simulated ICERs falling below the commonly accepted Australian willingness-to-pay threshold of AU$50,000 per QALY. EVT is cost-effective and associated with considerable clinical benefits relative to standard medical management for very elderly patients with LVO stroke. Our findings support the provision of EVT to the very elderly.